Illumina, Inc. announced on November 19, 2024, the upcoming release of TruSight™ Oncology 500 v2 (TSO 500 v2), a new version of its flagship cancer research assay. This solution is designed to enable comprehensive genomic profiling (CGP) of tumors.
The assay is currently under development, with a global release planned for mid-2025. Detailed plans for the product were shared at the annual meeting of the Association of Molecular Pathology (AMP).
This expansion of the TruSight Oncology portfolio reinforces Illumina's commitment to advancing cancer research and providing tools for deeper insights into tumor biology. The new assay is expected to enhance the capabilities available to researchers in the oncology field.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.